Last reviewed 2026-05-24 · How we verify

Ampamet (ANIRACETAM)

Phase 2 active Small molecule ✓ Verified May 2026

Ampamet (generic name: ANIRACETAM) is a aniracetam drug. It is currently in Phase 2 development.

Aniracetam works by enhancing the activity of glutamate receptors and increasing the release of the neurotransmitter acetylcholine.

Ampamet, also known as Aniracetam, is a small molecule. It is a synthetic compound with the chemical name 1-P-ANISOYL-2-PYRROLIDINONE.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ANIRACETAM
Drug class	aniracetam
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of it like a key that unlocks a door in your brain. Aniracetam helps turn up the volume on certain chemical signals that help us learn and remember new information. This can make it easier to focus and pay attention.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ampamet CI brief — competitive landscape report
Ampamet updates RSS · CI watch RSS

Frequently asked questions about Ampamet

What is Ampamet?

Ampamet (ANIRACETAM) is a aniracetam drug.

How does Ampamet work?

Aniracetam works by enhancing the activity of glutamate receptors and increasing the release of the neurotransmitter acetylcholine.

What is the generic name of Ampamet?

ANIRACETAM is the generic (nonproprietary) name of Ampamet.

What drug class is Ampamet in?

Ampamet belongs to the aniracetam class. See all aniracetam drugs at /class/aniracetam.

What development phase is Ampamet in?

Ampamet is in Phase 2.

Drug class: All aniracetam drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing